Skip to content
ChickenStockChickenStock
ResearchBCYC
Bicycle Therapeutics logo

Bicycle Therapeutics (BCYC) stock

NASDAQ

$3.21+0.94%(+0.03)

As of the Nov 17, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-1.60x

Net loss — not comparable

P/B

0.45x

P/S

2.68x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 183.3% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Oct 29, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

14 SEC filings
  • Lee KevinCHIEF EXECUTIVE OFFICER · Oct 5, 2026Open-market sale1,638 shares · $6K
    Avg. price $3.57595,866 shares held after
  • Skynner MichaelCHIEF SCIENTIFIC OFFICER · Oct 5, 2026Open-market sale503 shares · $2K
    Avg. price $3.57154,726 shares held after
  • Perry Jennifer ScottChief Operating Officer · Oct 5, 2026Open-market sale762 shares · $3K
    Avg. price $3.7486
    Show 4 price lots
    • 326 shares × $3.78$1K
    • 326 shares × $3.78$1K
    • 80 shares × $3.56$285
    • 30 shares × $3.57$107
  • Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF · Oct 5, 2026Open-market sale242 shares · $864
    Avg. price $3.5792,561 shares held after
  • Thompson Travis AlvinChief Financial Officer · Oct 5, 2026Open-market sale79 shares · $282
    Avg. price $3.5764,449 shares held after
  • Lee KevinCHIEF EXECUTIVE OFFICER · Oct 2, 2026Open-market sale6,167 shares · $21K
    Avg. price $3.47597,504 shares held after
  • Swanton Robert CharlesDirector · Oct 2, 2026Open-market sale3,431 shares · $12K
    Avg. price $3.4715,782 shares held after
  • Skynner MichaelCHIEF SCIENTIFIC OFFICER · Oct 2, 2026Open-market sale1,942 shares · $7K
    Avg. price $3.47155,229 shares held after
  • Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF · Oct 2, 2026Open-market sale1,572 shares · $5K
    Avg. price $3.4792,803 shares held after
  • Perry Jennifer ScottChief Operating Officer · Oct 2, 2026Open-market sale1,094 shares · $4K
    Avg. price $3.4789,958 shares held after
  • Thompson Travis AlvinChief Financial Officer · Oct 2, 2026Open-market sale893 shares · $3K
    Avg. price $3.4764,528 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Bicycle Therapeutics (BCYC) stock information

NASDAQ

Bicycle Therapeutics (BCYC) is listed on NASDAQ. Its market capitalization is about $225M. On trailing-twelve-month earnings the P/E ratio is -1.6, and the P/B ratio is 0.45. Return on equity is -27.9%. These figures are computed in-house from official filings and are reference information only.

Bicycle Therapeutics — frequently asked questions

What is the P/E ratio of Bicycle Therapeutics (BCYC)?
On a trailing-twelve-month basis, BCYC trades at a P/E ratio of -1.6. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Bicycle Therapeutics?
BCYC has a market capitalization of about $225M. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.